Cargando…

Immune response to racotumomab in a child with relapsed neuroblastoma

Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in clinical practice and other options may be pursued. We report the use of racotumomab, an anti-idiotype vaccine against N-gly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sampor, C., Guthmann, M. D., Scursoni, A., Cacciavillano, W., Torbidoni, A., Galluzzo, L., Camarero, S., Lopez, J., de Dávila, M. T. G., Fainboim, L., Chantada, G. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526767/ https://www.ncbi.nlm.nih.gov/pubmed/23267436 http://dx.doi.org/10.3389/fonc.2012.00195

Ejemplares similares

Detection of N-Glycolyl GM3 Ganglioside in Neuroectodermal Tumors by Immunohistochemistry: An Attractive Vaccine Target for Aggressive Pediatric Cancer
por: Scursoni, Alejandra M., et al.
Publicado: (2011)

Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data
por: Vázquez, Ana M., et al.
Publicado: (2012)

Preclinical evaluation of racotumomab, an anti-idiotype monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer
por: Segatori, Valeria I., et al.
Publicado: (2012)

Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3
por: Guthmann, Marcelo D., et al.
Publicado: (2013)

Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression in Patients Receiving Racotumomab Immunotherapy
por: Uskent, Necdet, et al.
Publicado: (2020)

The Clinical Features of Patients with Chronic Hepatitis C Virus Infections Are Associated with Killer Cell Immunoglobulin-Like Receptor Genes and Their Expression on the Surface of Natural Killer Cells
por: Podhorzer, Ariel, et al.
Publicado: (2018)

CAR T Cell Therapy for Neuroblastoma
por: Richards, Rebecca M., et al.
Publicado: (2018)

Human CD8(+)HLA-DR(+) Regulatory T Cells, Similarly to Classical CD4(+)Foxp3(+) Cells, Suppress Immune Responses via PD-1/PD-L1 Axis
por: Machicote, Andres, et al.
Publicado: (2018)

Beliefs and Determinants of Use of Traditional Complementary/Alternative Medicine in Pediatric Patients Who Undergo Treatment for Cancer in South America
por: Rocha, Valeria, et al.
Publicado: (2017)

Aberrant O-glycosylation modulates aggressiveness in neuroblastoma
por: Cuello, Hector A., et al.
Publicado: (2018)

Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al
por: Mora, Jaume, et al.
Publicado: (2021)

Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
por: Padovan-Merhar, Olivia M., et al.
Publicado: (2016)

Host Immune Evasion by Lyme and Relapsing Fever Borreliae: Findings to Lead Future Studies for Borrelia miyamotoi
por: Stone, Brandee L., et al.
Publicado: (2017)

Immune Thrombocytopenia in a Child with Neuroblastoma
por: Ikizoglu, Hasan Tarkan, et al.
Publicado: (2017)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Novel Therapies for Relapsed and Refractory Neuroblastoma
por: Zage, Peter E.
Publicado: (2018)

Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma
por: Aschero, Rosario, et al.
Publicado: (2021)

Immune Evasion Strategies of Relapsing Fever Spirochetes
por: Röttgerding, Florian, et al.
Publicado: (2020)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020)

MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database
por: Zhang, Peng, et al.
Publicado: (2017)

Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Neuroblastoma presenting as hip pain and skull prominence in a child
por: Hewitt, Hunter R., et al.
Publicado: (2019)

The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse
por: Riehl, Lara M., et al.
Publicado: (2015)

Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2(+) Murine Neuroblastoma
por: Bates, Paul D., et al.
Publicado: (2021)

Identification of hub genes and their correlation with infiltration of immune cells in MYCN positive neuroblastoma based on WGCNA and LASSO algorithm
por: Chen, Ji, et al.
Publicado: (2022)

Construction of a novel anoikis-related prognostic model and analysis of its correlation with infiltration of immune cells in neuroblastoma
por: Chen, Ji, et al.
Publicado: (2023)

Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis
por: Kashani, Nicole, et al.
Publicado: (2021)

The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors
por: Le, Thanh-Phuong, et al.
Publicado: (2017)

Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments
por: Corallo, Diana, et al.
Publicado: (2020)

Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
por: Tang, Xao X., et al.
Publicado: (2021)

Single-cell transcriptome sequencing reveals tumor heterogeneity in family neuroblastoma
por: Zhang, Yunlong, et al.
Publicado: (2023)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

Lessons from Pasteur may help prevent the deadly relapse of Ebola in patients: Using contingency vaccination to avoid Ebola relapse in immune-privileged organs
por: Ye, Wei, et al.
Publicado: (2023)

A novel ganglioside-related risk signature can reveal the distinct immune landscape of neuroblastoma and predict the immunotherapeutic response
por: Yang, Jiaxing, et al.
Publicado: (2022)

CD24-Fc suppression of immune related adverse events in a therapeutic cancer vaccine model of murine neuroblastoma
por: Wu, Xiaofang, et al.
Publicado: (2023)

B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6mbjcassq2h2rl27lpde3mbuje